In EGFR-overexpressing MDA-MB-468 breast cancer cells, the combined use of cetuximab and matuzumab (anti-EGFR mAbs) decreased growth and survival to a greater extent than the use of a single Ab treatment [22]. This evidence concerns the gene EGFR and breast cancer.